Natalija Dedić Plavetić

University Hospital Centre Zagreb

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Damir Vrbanec

Juraj Dobrila University of Pula

Tajana Silovski

University of Zagreb

Ana Kulić

University Hospital Centre Zagreb

Jasminka Jakić‐Razumović

University of Zagreb

RŠ

Robert Šeparović

University Hospital Centre Zagreb

Maja Sirotković-Skerlev

University Hospital Centre Zagreb

Marina Popović

University Hospital Centre Zagreb

Paula Podolski

University Hospital Centre Zagreb

Marija Križić

University Hospital Centre Zagreb

Anuška Budisavljević

Juraj Dobrila University of Pula

Cooperative Institutions

University Hospital Centre Zagreb

136

University of Zagreb

120

Klinički Bolnički Centar Rijeka

University of Split

University Hospital Dubrava

Opća Bolnica Varaždin

Sisters of Charity Hospital

University of Rijeka

University of Osijek

University of Ioannina

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

1846P The impact of newly diagnosed early breast cancer on distress, perception of health and psychologic resilience

Annals of Oncology (2023)

Anuška Budisavljević Natalija Dedić Plavetić Kristina Klaric Renata Kelemenić-Dražin Marina Letica Crepulja

Depression

Perceived Stress Scale

Patient Health Questionnaire

10.1016/j.annonc.2023.09.2797

Cite

Citations (0)

Metakroni karcinom gušterače nakon karcinoma bubrega-etiopatogenetski osvrt i prikaz bolesnice

Marina Barić Marina Vidović Natalija Dedić Plavetić Mate Škegro

Tera-

Source

Cite

Citations (0)

Low serum MMP-1 in breast cancer: a negative prognostic factor?

Biomarkers (2012)

Ana Kulić Natalija Dedić Plavetić Jurica Vrbanec Maja Sirotković-Skerlev

In this study we investigated the prognostic significance of serum matrix metalloproteinase (MMP)-1 levels in early-stage breast cancer patients and correlated these levels with various clinicopathologic parameters. MMP-1 levels were determined by enzyme-linked immunosorbent assay. MMP-1 serum levels in patients (n = 60) were significantly lower than in healthy subjects (n = 20, p < 0.0001). We found significant negative correlation between serum levels of MMP-1 and several negative prognostic factors of breast cancer. Kaplan–Meier analysis showed significantly shorter 5-year survival in patients with lower values of MMP-1 compared to those with high levels of MMP-1 (p = 0.0147). Our results suggest a negative prognostic role of low serum MMP-1.

Clinical Significance

10.3109/1354750x.2012.678885

Cite

Citations (11)

Hrvatske smjernice za genetičko savjetovanje i testiranje na nasljedni rak dojke i jajnika

Boris Brkljačić Natalija Dedić Plavetić Herman Haller Sonja Levanat Paula Podolski

Source

Cite

Citations (0)

Long-term outcome of patients with luminal A breast cancer surrogate subtype according to chromosomal instability measured by securin expression

The Breast (2019)

Natalija Dedić Plavetić MM Lovric Mirna Majzec Ana Kulić Maja Sirotković-Skerlev

Securin

Surrogate endpoint

Chromosome instability

10.1016/s0960-9776(19)30351-0

Cite

Citations (0)

PRAĆENJE ONKOLOŠKIH BOLESNIKA – KLINIČKE PREPORUKE HRVATSKOG DRUŠTVA ZA INTERNISTIČKU ONKOLOGIJU HLZ-a V. dio: melanom, sarkomi, tumori središnjega živčanog sustava, rak pluća

Liječnički vjesnik (2017)

Davorin Herceg Marko Jakopović Natalija Dedić Plavetić Miroslav Samaržija Branka Čučević

Source

Cite

Citations (0)

Praćenje onkoloških bolesnika - kliničke preporuke Hrvatskog društva za internističku onkologiju HLZ- a 1. dio: rak dojke, rak tijela maternice, rak vrata maternice, rak jajnika

Liječnički vjesnik (2016)

Robert Šeparović Tajana Silovski Natalija Dedić Plavetić Alan Šerman Filip Grubišić Čabo

Source

Cite

Citations (0)

Prognostic value of proliferation markers expression in breast cancer

Medical Oncology (2013)

Natalija Dedić Plavetić Jasminka Jakić‐Razumović Ana Kulić Damir Vrbanec

Survivin

Hematology

Tissue microarray

Cyclin B1

Proliferation index

Proliferation Marker

10.1007/s12032-013-0523-x

Cite

Citations (19)

Next-Generation Sequencing of Circulating Tumor DNA Can Optimize Second-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer after Progression on anti-EGFR Therapy: Time to Rethink Our Approach

Oncology Research and Treatment (2022)

Davide Mauri Konstantinos Kamposioras Dimitrios Matthaios Maria Tolia Ioanna Nixon

Management of Ras wild-type colorectal cancer (CRC) patients upon disease progression after the successful use of targeted treatment with anti-EGFR monoclonal antibodies and backbone chemotherapy remains a clinical challenge.Development of treatment resistance with prevalence of preexisting RAS mutated clones, RAS mutation conversion, truncation of extracellular receptor domains as well as HER2 and MET amplification are molecular events that can be difficult to follow without the use of sophisticated laboratory techniques. The clinical hurdle of re-biopsy and tumor heterogeneity can be overcome by the implementation of next-generation sequencing (NGS) to analyze circulating tumor DNA (ctDNA) and identify druggable mutations or recovery of RAS-wildness. In this opinion paper, we summarize with critical thinking the clinical approach to be followed after the failure of first-line treatment in Ras wild-type CRC tumors with the use of NGS. Rechallenge with anti-EGFR inhibitors, in case of persistent or recovery of RAS-wildness, and targeted approach of specific mutations (BRAF inhibitors), amplifications (anti-Her2 treatment), or fusion proteins (NTRK inhibitors) can by guided by the use of NGS. The use of NGS platforms for serial analysis of ctDNA is an important step to better understand the molecular landscape of metastatic CRC and guide clinical decisions.NGS should be considered a mainstay in clinical practice for the management of CRC patients and health authorities should consider reimbursing its use in the appropriate clinical settings.

Panitumumab

Liquid biopsy

Eribulin

Targeted Therapy

Druggability

10.1159/000521845

Cite

Citations (4)

Associations between PIK3CA Mutations and Disease Free Survival in Patients with HR+, HER2− Tumors Treated with Adjuvant Hormonal Therapy: A Real‐World Study in Croatia

The Breast Journal (2024)

Dora Čerina Natalija Dedić Plavetić Ingrid Belac-Lovasić Robert Šeparović Josipa Flam

Disease recurrence in patients with the early hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast tumor subtype is particularly challenging to manage due to its complex and very heterogeneous biological nature. Namely, due to primary and secondary resistance, one-quarter of patients with early-stage disease will experience disease recurrence. This variability in the timing of recurrence highlights the need to better identify key biomarkers that could predict therapeutic outcomes and guide personalized treatment strategies for these patients. Mutations in the phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) gene are highly prevalent (30-40%) in HR+/HER2- advanced breast cancer. They lead to activation of the PI3K/AKT/mTOR pathway, promoting cell growth, and proliferation, and are associated with poor prognosis in advanced breast cancer. Our aim was to examine the association between and impact of PIK3CA mutation status on disease-free survival (DFS) in HR+/HER2- early breast cancer patients.

Hormonal Therapy

Adjuvant Therapy

10.1155/2024/5648845

Cite

Citations (0)